

Wajahat Z Mehal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1668056/publications.pdf>

Version: 2024-02-01

78
papers

8,764
citations

101543

36
h-index

69250

77
g-index

80
all docs

80
docs citations

80
times ranked

13835
citing authors

#	ARTICLE	IF	CITATIONS
1	A digital pathology tool for quantification of color features in histologic specimens. <i>Bioengineering and Translational Medicine</i> , 2022, 7, e10242.	7.1	1
2	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 765-767.	3.7	2
3	GSK3 β mediates the spatiotemporal dynamics of NLRP3 inflammasome activation. <i>Cell Death and Differentiation</i> , 2022, 29, 2060-2069.	11.2	17
4	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 125-134.	5.0	3
5	Immunological mechanisms and therapeutic targets of fatty liver diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 73-91.	10.5	98
6	From mice to humans: Unravelling the genetic levers of NASH. <i>Journal of Hepatology</i> , 2020, 73, 749-751.	3.7	0
7	Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. <i>Current Transplantation Reports</i> , 2020, 7, 332-339.	2.0	0
8	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 70, 1443-1456.	7.3	11
9	The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis. <i>Hepatology</i> , 2019, 70, 741-744.	7.3	4
10	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 444-454.	0.9	1
11	NASH and HCC Are Driven by Different Signaling Pathways with a Common Regulator. <i>Cell Metabolism</i> , 2019, 29, 3-4.	16.2	16
12	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	3.7	144
13	Role of sterile inflammation in fatty liver diseases. <i>Liver Research</i> , 2018, 2, 21-29.	1.4	8
14	A leukocyte activation test identifies food items which induce release of DNA by innate immune peripheral blood leucocytes. <i>Nutrition and Metabolism</i> , 2018, 15, 26.	3.0	4
15	β -Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. <i>Journal of Hepatology</i> , 2018, 69, 687-696.	3.7	48
16	Acetyl-Coenzyme A carboxylase inhibition Delivers, as Anticipated, for Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1304-1306.	1.3	2
17	The multi-dimensional role of intestinal HIFs in liver pathobiology. <i>Journal of Hepatology</i> , 2018, 69, 772-773.	3.7	1
18	Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000164.	2.7	27

#	ARTICLE	IF	CITATIONS
19	Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1571-1581.	5.6	140
20	Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. <i>JCI Insight</i> , 2017, 2, e90780.	5.0	181
21	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2829-2841.	8.2	336
22	The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. <i>Biochemical Pharmacology</i> , 2016, 112, 90-101.	4.4	22
23	New approaches for fibrosis regression in alcoholic cirrhosis. <i>Hepatology International</i> , 2016, 10, 773-778.	4.2	6
24	We are not in kansas anymore: The unfamiliar landscape of NASH. <i>Hepatology</i> , 2016, 63, 682-684.	7.3	2
25	Caspase-12, but Not Caspase-11, Inhibits Obesity and Insulin Resistance. <i>Journal of Immunology</i> , 2016, 196, 437-447.	0.8	16
26	Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 027-036.	3.6	35
27	DNA: Adding injury to insult. <i>Hepatology</i> , 2015, 61, 35-36.	7.3	2
28	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	7.3	230
29	Inflammasomes in pancreatic physiology and disease. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G643-G651.	3.4	47
30	Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 1305-1315.	5.4	28
31	Who is the scientist in bio-medical research, the author or the reviewer?. <i>Frontiers in Pharmacology</i> , 2014, 5, 50.	3.5	1
32	Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb. <i>Frontiers in Pharmacology</i> , 2014, 5, 69.	3.5	31
33	Constitutive NLRP3 activation: Too much of a bad thing. <i>Hepatology</i> , 2014, 59, 761-763.	7.3	2
34	Food Reactivity on the ALCAT Leukocyte Activation Test Is Associated with Upregulation of CD11b on T Cells. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, A35-A36.	2.1	0
35	The Gordian Knot of dysbiosis, obesity and NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 637-644.	17.8	134
36	Sterile inflammation in the liver and pancreas. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 61-67.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Therapeutic strategies in inflammasome mediated diseases of the liver. <i>Journal of Hepatology</i> , 2013, 58, 1047-1052.	3.7	31
38	Inflammasome biology in fibrogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 979-988.	3.8	54
39	Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1992-2003.	4.1	49
40	A Novel Small-Molecule Enantiomeric Analogue of Traditional (μ)-Morphinans Has Specific TLR9 Antagonist Properties and Reduces Sterile Inflammation-Induced Organ Damage. <i>Journal of Immunology</i> , 2013, 190, 4297-4304.	0.8	27
41	Sterile Inflammatory Response in Acute Pancreatitis. <i>Pancreas</i> , 2012, 41, 353-357.	1.1	118
42	P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1171-G1179.	3.4	133
43	Adenine Induces Differentiation of Rat Hepatic Stellate Cells. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2371-2378.	2.3	11
44	HIF-1 α is a major and complex player in alcohol induced liver diseases. <i>Journal of Hepatology</i> , 2012, 56, 311-312.	3.7	15
45	Sterile Inflammation in the Liver. <i>Gastroenterology</i> , 2012, 143, 1158-1172.	1.3	553
46	Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. <i>Nature</i> , 2012, 482, 179-185.	27.8	2,026
47	Gaucher disease gene <i>GBA</i> functions in immune regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10018-10023.	7.1	70
48	The gut-liver axis: A busy two-way street. <i>Hepatology</i> , 2012, 55, 1647-1649.	7.3	24
49	Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20095-20100.	7.1	91
50	TLR9 and the NLRP3 Inflammasome Link Acinar Cell Death With Inflammation in Acute Pancreatitis. <i>Gastroenterology</i> , 2011, 141, 358-369.	1.3	241
51	Scraping fibrosis: Expressway to the core of fibrosis. <i>Nature Medicine</i> , 2011, 17, 552-553.	30.7	180
52	Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. <i>Toxicology and Applied Pharmacology</i> , 2011, 252, 165-175.	2.8	66
53	Adenosine inhibits chemotaxis and induces hepatocyte-specific genes in bone marrow mesenchymal stem cells. <i>Hepatology</i> , 2010, 51, NA-NA.	7.3	22
54	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatory response in the CCl4-cirrhotic liver. <i>Liver International</i> , 2010, 30, 988-994.	3.9	16

#	ARTICLE	IF	CITATIONS
55	Cell Death and Fibrogenesis. <i>Seminars in Liver Disease</i> , 2010, 30, 226-231.	3.6	62
56	Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19473-19478.	7.1	198
57	Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. <i>Hepatology</i> , 2009, 49, 185-194.	7.3	82
58	HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α -2a and Ribavirin. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 477-481.	2.2	29
59	Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. <i>Journal of Clinical Investigation</i> , 2009, 119, 305-14.	8.2	493
60	Colchicine-associated Ring Mitosis in Liver Biopsy and Their Clinical Implications. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 1060-1062.	2.2	9
61	Adenosine Deamination Sustains Dendritic Cell Activation in Inflammation. <i>Journal of Immunology</i> , 2007, 179, 1884-1892.	0.8	121
62	Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G395-G401.	3.4	71
63	Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. <i>Hepatology</i> , 2007, 46, 1509-1518.	7.3	220
64	Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis. <i>Science</i> , 2006, 311, 847-851.	12.6	1,003
65	Modulation of Cell Adhesion and Motility in the Immune System by Myo1f. <i>Science</i> , 2006, 314, 136-139.	12.6	102
66	In Vitro and In Vivo Protection of Stellate Cells from Apoptosis by Leptin. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1697-1705.	2.3	36
67	Critical role for the α regulatory subunits of Cav channels in T lymphocyte function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15529-15534.	7.1	101
68	Blocking intrahepatic deletion of activated CD8+ T cells by an altered peptide ligand. <i>Cellular Immunology</i> , 2005, 238, 31-37.	3.0	3
69	TGF- β 2 signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions. <i>International Immunology</i> , 2005, 17, 531-538.	4.0	15
70	Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10. <i>Journal of Immunology</i> , 2005, 175, 3577-3583.	0.8	17
71	Requirement of Voltage-Gated Calcium Channel α 4 Subunit for T Lymphocyte Functions. <i>Science</i> , 2005, 307, 117-121.	12.6	22
72	Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver. <i>Hepatology</i> , 2004, 39, 1017-1027.	7.3	44

#	ARTICLE	IF	CITATIONS
73	Phosphatidylserine Receptor Is Required for Clearance of Apoptotic Cells. <i>Science</i> , 2003, 302, 1560-1563.	12.6	368
74	Intrahepatic T cell survival versus death: which one prevails and why?. <i>Journal of Hepatology</i> , 2003, 39, 1070-1071.	3.7	8
75	Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. <i>Hepatology</i> , 2002, 36, 49-54.	7.3	78
76	Involvement of CD1 in Peripheral Deletion of T Lymphocytes Is Independent of NK T Cells. <i>Journal of Immunology</i> , 2001, 166, 3090-3097.	0.8	15
77	Antigen Presentation by Liver Cells Controls Intrahepatic T Cell Trapping, Whereas Bone Marrow-Derived Cells Preferentially Promote Intrahepatic T Cell Apoptosis. <i>Journal of Immunology</i> , 2001, 167, 667-673.	0.8	83
78	A prognostic rule for elderly patients admitted with community-acquired pneumonia. <i>American Journal of Medicine</i> , 1999, 106, 20-28.	1.5	155